Eli Lilly and Company (LLY)
| Market Cap | 928.64B +31.0% |
| Revenue (ttm) | 59.42B +45.4% |
| Net Income | 18.41B +120.0% |
| EPS | 20.44 +121.0% |
| Shares Out | 895.38M |
| PE Ratio | 50.74 |
| Forward PE | 33.02 |
| Dividend | $6.92 (0.67%) |
| Ex-Dividend Date | Feb 13, 2026 |
| Volume | 3,303,147 |
| Open | 1,033.30 |
| Previous Close | 1,024.14 |
| Day's Range | 1,020.00 - 1,048.57 |
| 52-Week Range | 623.78 - 1,133.95 |
| Beta | 0.35 |
| Analysts | Strong Buy |
| Price Target | 1,104.00 (+6.45%) |
| Earnings Date | Feb 4, 2026 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price target is $1,104.0, which is an increase of 6.45% from the latest price.
News
Jim Cramer on what is driving Eli Lilly's stock right now
'Mad Money' host Jim Cramer looks ahead to next week's market moving moments.
Cramer's week ahead: Earnings from Eli Lilly, Alphabet and Amazon. Plus, jobs data
CNBC's Jim Cramer said Friday that the market's subdued finish to the week could be a good thing ahead of a busy earnings slate. AMD, Alphabet and Amazon are all set to report quarterly results.
Eli Lilly CEO says Medicare coverage of obesity drugs could 'change the game' for upcoming pill launch
Eli Lilly CEO Dave Ricks said upcoming Medicare coverage of obesity drugs could be a major catalyst for the launch of the company's closely watched experimental obesity pill, orforglipron. The launch ...
Eli Lilly to build $3.5 billion Pennsylvania plant in US manufacturing push
Eli Lilly announced on Friday that it will build a pharmaceutical manufacturing facility in Pennsylvania, its fourth new site in an effort to expand U.S. production and bolster medical supply chains.
Eli Lilly plans $3.5 billion manufacturing plant in Pennsylvania to make next-generation obesity injections
Eli Lilly said it will spend $3.5 billion to build a manufacturing plant in Lehigh Valley, Pennsylvania, that will help make its next-generation obesity drugs. That includes a closely watched experime...
Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility
The $3.5 billion Lehigh Valley site will develop Lilly's next-generation weight-loss medicines, including retatrutide Company plans to create more than 2,800 manufacturing and construction jobs at Lil...
Pennsylvania Wins Bid for Eli Lilly Weight-Loss Drug Factory
The region is attempting to build on its status as a manufacturing hub with bigger investments and more tax perks for corporate investors.
Eli Lilly: Obesity Pricing For Access Tradeoff A Net Positive
Eli Lilly enters 2026 with strong commercial momentum, pipeline wins, and shares near all-time highs. The company's strategic price cuts for Zepbound and commitment to a low-priced launch of orforglip...
Eli Lilly Teams Up With Two Biotechs To Target Autoimmune Disease, Hearing Loss In Deals Worth $3 Billion
Repertoire Immune Medicines entered a strategic collaboration on Thursday with Eli Lilly and Co. (NYSE: LLY) to develop tolerizing therapies for multiple autoimmune diseases.
Trump says Eli Lilly to build six US plants
U.S. President Donald Trump said on Thursday that he has spoken to the head of pharmaceutical company Eli Lilly and that the company plans to build six plants in the country.
Lilly signs up to $1.93 billion deal with Repertoire for autoimmune therapies
Drugmaker Eli Lilly is partnering with Repertoire Immune Medicines in a deal worth up to $1.93 billion to develop therapies for multiple autoimmune diseases, the Massachusetts-based biotech said on Th...
Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless
U.S. drugmaker Eli Lilly signed an agreement worth up to $1.12 billion with Seamless Therapeutics, the Germany-based startup said on Wednesday, to develop and commercialize treatments for hearing loss...
Exclusive: Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows
Novo Nordisk spent nearly $500 million on U.S. advertising for its GLP-1 drugs Wegovy and Ozempic in the first nine months of 2025, more than double what Eli Lilly shelled out for its rival medicines,...
US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks
The U.S. Centers for Medicare & Medicaid Services on Tuesday named a new group of branded drugs from major pharmaceutical companies including Eli Lilly , Pfizer and AbbVie for the third cycle of the M...
Novo Nordisk Vs. Eli Lilly: The Tide May Be Turning For The Underdog
Novo Nordisk was excessively punished by the market, trading at a significant discount to Eli Lilly despite robust fundamentals and global leadership in metabolic disease. NVO's global infrastructure,...
What obesity drugmakers see next in the market: More pills, easier access and drug combinations
Top executives from drugmakers big and small told CNBC that the next phase of the obesity drug market will be defined by a broader range of treatment options and improved access for patients. CNBC spo...
Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement
INDIANAPOLIS, Jan. 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2025 financial results on February 4, 2026. Lilly will also conduct a conference call tha...
Eli Lilly: Breakout To New Highs Sends A Clear Warning Shot
Eli Lilly remains the dominant force in obesity drugs, with strong momentum ahead of its anticipated Q2 oral obesity drug launch. Eli Lilly's oral drug entry is expected to lower barriers for new pati...
Eli Lilly: Buy Ahead Of Its Earnings Day (Preview)
Eli Lilly's forward P/E has compressed below 26x FY2027, while consensus earnings estimates for 2027–2030 continue to rise, signaling undervaluation versus growth. The upcoming oral GLP-1 orforglipron...
Polen Focus Growth Portfolio Q4 2025 Performance, Attribution & Portfolio Activity
Eli Lilly's stock price has underperformed this year, much of it on the back of drug pricing concerns, potential tariff impacts and, perhaps, less enthusiasm for GLP-1 drugs. The primary drag for the ...
Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer
INDIANAPOLIS, Jan. 20, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabar...
Abivax CEO dismisses 'noise' around rumored Eli Lilly bid
Abivax Chief Executive Marc de Garidel dismissed as "noise" reports in the French press that pharmaceutical giant Eli Lilly may take over his company, and said market speculation about an ongoing revi...
Eli Lilly, Nvidia team up in a $1B AI innovation lab.
Eli Lilly, Nvidia team up in a $1B AI innovation lab.